Vera Therapeutics Inc. (VERA)
NASDAQ: VERA
· Real-Time Price · USD
23.70
0.33 (1.41%)
At close: May 01, 2025, 3:59 PM
24.21
2.15%
After-hours: May 01, 2025, 04:11 PM EDT
1.41% (1D)
| Bid | 22.7 |
| Market Cap | 1.51B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -152.15M |
| EPS (ttm) | -2.75 |
| PE Ratio (ttm) | -8.62 |
| Forward PE | -7.44 |
| Analyst | Buy |
| Ask | 25 |
| Volume | 1,417,223 |
| Avg. Volume (20D) | 951,754 |
| Open | 23.51 |
| Previous Close | 23.37 |
| Day's Range | 22.70 - 23.88 |
| 52-Week Range | 18.53 - 51.61 |
| Beta | 1.27 |
About VERA
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of ...
Industry Biotechnology
Sector Healthcare
IPO Date May 14, 2021
Employees 112
Stock Exchange NASDAQ
Ticker Symbol VERA
Website https://veratx.com
Analyst Forecast
According to 8 analyst ratings, the average rating for VERA stock is "Buy." The 12-month stock price forecast is $61, which is an increase of 157.38% from the latest price.
Stock Forecasts3 months ago
-6.08%
Vera Therapeutics shares are trading lower. The co...
Unlock content with
Pro Subscription
6 months ago
-9.23%
Vera Therapeutics shares are trading lower after the company announced plans to commence a public offering to issue and sell $300 million of its Class A common stock.
